Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2018-03-20 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Mereo selected for oral presentation at ATS 2018
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service). It announces that Mereo BioPharma has been selected to present clinical trial data at an upcoming medical conference. It does not contain financial statements, board changes, or dividend declarations, but rather serves as a general corporate update regarding clinical progress. As it does not fit into more specific categories like 'Earnings Release' or 'Investor Presentation', it is classified as a general regulatory filing.
2018-03-20 English
Mereo: Positive Top-Line Results for BGS-649
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It announces positive top-line clinical trial results for a specific drug candidate (BGS-649). While it contains detailed trial data, it is an initial announcement of results rather than a full financial report or a standalone audit. In the context of corporate filings, such announcements of clinical trial outcomes are classified as Regulatory Filings (RNS) as they serve as the primary disclosure mechanism for material company news.
2018-03-19 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 100% confidence The document is a Form F-1 Registration Statement filed confidentially with the SEC, related to an initial public offering (IPO) of securities by Mereo BioPharma Group plc. It includes detailed information typical of a prospectus such as risk factors, business overview, management discussion, financial data, underwriting details, and legal matters. The presence of a registration statement under the Securities Act of 1933 and the detailed offering information indicates this is a capital raising filing. This type of document is best classified as a Capital/Financing Update (CAP) because it relates to the company's fundraising activities through a public offering of shares. It is not an annual or interim report, audit report, or earnings release, nor is it a proxy or governance document. The length and content confirm it is not merely an announcement but the actual registration statement/prospectus document.
2018-03-14 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 100% confidence The document is a Form F-1 Registration Statement filed confidentially with the U.S. Securities and Exchange Commission (SEC) for Mereo BioPharma Group plc. It is an initial public offering (IPO) prospectus, including detailed information about the company, its business, risk factors, financial data, management, and offering details. The document is a registration statement under the Securities Act of 1933, which is used to register securities for public offering. This type of filing is related to capital raising and financing activities. It is not an annual report, earnings release, or other types of reports but a capital markets document for the IPO process. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering and financial information, consistent with a capital raising filing.
2018-02-27 English
Mereo BioPharma Appoints Wills Hughes-Wilson
Board/Management Information Classification · 100% confidence The document is an official announcement from Mereo BioPharma Group plc regarding the appointment of a new Head of Patient Access and Commercial Planning. This falls under the category of senior management changes. While it is distributed via the RNS (Regulatory News Service), the content is specifically about a personnel appointment, which aligns with the 'Board/Management Information' category.
2018-02-26 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 Registration Statement filed confidentially with the U.S. Securities and Exchange Commission (SEC) for Mereo BioPharma Group plc. It is a detailed registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes extensive prospectus information, risk factors, business overview, financial data, and underwriting details. This type of filing is related to capital raising and securities registration rather than a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPO registration statements.
2018-01-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.